Double Threat Intro Close: Actinium Pharmaceuticals, Inc. (ATNM)

There’s only one stock we know of that has analysts screaming BUY! Advertisement | [Unsubscribe]( Here's our last update for the day... don't miss this opportunity: Actinium Pharmaceuticals (NYSE: ATNM). There’s only one stock we know of that has analysts screaming BUY! And has the potential to help so many of our friends and neighbors. In fact, Cantor Fitzgerald is targeting a 182% move to the upside turning every $10,000 into over $28,000. That’s because more and more people everyday are in dire need of the solution that this company could provide. That company is Actinium Pharmaceuticals (NYSE: ATNM) - a clinical-stage biopharmaceutical company developing targeted radiotherapies to deliver cancer-killing radiation with cellular level precision to treat patients with high unmet needs not addressed by traditional cancer therapies. It’s time for Big Pharma to step aside and let real companies with real solutions start helping everyday people. And we believe that it’s actually in YOUR best interest to do so. Remember, there’s a potential 182% windfall at stake here. Now, let me be very clear… This is a speculative biotech play but if the results are anything to go by - this could be one of the highest confidence biotech opportunities in the market right now. That’s because it’s gearing up to report topline results for its Phase 3 SIERRA study. And with the incredible results from its Phase 2 study, such as a 5-times greater difference than the control, we could be looking at national coverage and some of the biggest names on the street taking notice. This clinical-stage biopharmaceutical company could completely revolutionize medicine. Actinium Pharmaceuticals (NYSE: ATNM) could be the latest and most significant find in the biotech sector. It has a potentially revolutionary treatment rapidly progressing and the possibility to change the face of medicine as we know it. And analysts see it. If you don’t watch this one closely, you may regret it. Check out my complete report below for more key details. ----- Actinium Pharmaceuticals, Inc. (ATNM) There is demand for a leukemia cure, and the market looks lucrative. The [leukemia therapeutics market]( could reach $17.1Bn by 2024 up from $12.3Bn in 2019, at a CAGR of 6.8%. Do you know what’s driving this market? A rising prevalence of acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML). [Grab The Full ATNM Company Report Here.]( Some must also contend with relapsed, or recurrent, [acute myelogenous leukemia (AML)]( which means leukemia came back after treatment and after reaching remission. Refractory AML means leukemia did not respond to treatment. Complete remission can’t be achieved because chemotherapy wasn’t able to kill off enough leukemia cells. The increasing number of approvals of novel and innovative drugs and immunotherapies is evidence of an increasing need for leukemia therapies. Say hello to a wide-open opportunity for Actinium Pharmaceuticals (ATNM). Product Pipeline: Iomab-B (Phase 3) Iomab-B is currently being studied in the pivotal Phase 3 SIERRA (Study of Iomab-B in Elderly Relapsed or Refractory AML) trial, a 150-patient, randomized controlled clinical trial in patients with relapsed or refractory acute myeloid leukemia (AML) who are age 55 and above. Patient enrollment in the SIERRA trial was completed in the third quarter of 2021 and the last patient on SIERRA was transplanted in the fourth quarter of 2021. And according to this recent press release, (ATNM) appears to be nearing some Q4 topline data. Check it out: Actinium Pharmaceuticals Announces Iomab-B SIERRA Trial Database Lock, Provides Corporate Update Highlighting Key Upcoming Milestones - On track to report topline data from the Pivotal Phase 3 SIERRA trial for Iomab-B in Q4 2022 - Overall survival data from the Actimab-A CLAG-M combination trial expected in Q4 2022 - Additional updates on collaborations and pipeline progress demonstrating Actinium's leadership in the development of Actinium-225-based radiotherapies expected by year-end - Approximately $116Mn in cash and cash equivalents at the end of Q2 2022 expected to fund key value creating clinical, regulatory and R&D milestones through mid-2025 NEW YORK, Sept. 21, 2022 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies, today provided a business update and outlook, highlighting upcoming clinical milestones. Key milestones expected before year-end include: topline results for the pivotal Phase 3 SIERRA trial for Iomab-B; survival data from the Actimab-A CLAG-M trial; and additional updates related to progress with the Company's collaborations and internal research programs. … [Read the full article here.]( Actinium Announces Positive 1-Year and 2-Year Overall Survival Data for Patients with Relapsed or Refractory AML in Phase 1 Actimab-A CLAG-M Combination Trial - 53% 1-year Overall Survival and 32% 2-year Overall Survival are approximately double outcomes with current approaches - Patients on study received a median of 2 lines of prior therapy with 57% receiving prior treatment with venetoclax and 67% had adverse cytogenetics with 52% of patients having a TP53 mutation - Data accepted for oral presentation at the 64th American Society of Hematology (ASH) Annual Meeting & Symposium on Saturday, December 10th at 10:30 AM CT [Read the full article here.]( Could this upcoming data become the catalyst to provide (ATNM) with a breakout spark? ----- Strong Analyst Coverage - Price Targets Galore Chew on this for a second: [Source]( This is saying something when you consider that ATNM was trading in the $7.00 range only 3 weeks ago... And has already exploded to a high of $15.12. But the fireworks are only just beginning... [Grab The Full ATNM Company Report Here.]( HC Wainwright analyst, Joseph Pantginis, has even tagged ATNM with a $45.00 target that gives ATNM over 444% potential upside from yesterday's close. Now, do we expect ATNM to go surging to any of those price target levels in the near term? No. But, with 4 targets nearly 100% higher than its current trading levels paints the portrait of a profile that may be significantly undervalued at this very moment. ----- Low Float - Strong Potential For Volatility ATNM is a low float profile. With [Yahoo Finance]( reporting it to have around 24.29Mn shares in its float, volatility could pop up at any moment. This is important for one key reason. If a low float company is able to produce good news, there are so few shares available for trading that sharp price spikes (volatility) can become a reality. So with Q4 topline data right around the corner, who knows what could be at stake for ATNM in the near term. ----- As soon as there are any updates today, I’ll be back to you with key information. Until then, Actinium Pharmaceuticals (ATNM) to the top of your watch-list. That it for today Warriors... talk soon. Benjamin Bull Editor, Wall St. Warrior Wall St. Warrior (wallstwarrior.com) and Dollar Stock Club (dollarstockclub.com) are owned by Guardian Financial Publishing LLC, a limited liability company. Disclosure: I am not a fin-an-cial adviser. All potential percentage gains are based on from the low to the high of day. Wall St. Warrior and Dollar Stock Club full disclosure is to be read and fully understood before using Wall St. Warrior and Dollar Stock Club website, or joining Wall St. Warrior and Dollar Stock Clubs’ email or text list. By viewing Wall St. Warrior and Dollar Stock Club website and/or reading Wall St. Warrior and Dollar Stock Clubs email or text newsletter you are agreeing to Wall St. Warrior and Dollar Stock Club’s full disclosure which can be read at Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. Wall St. Warrior (wallstwarrior.com) and Dollar Stock Club (dollarstockclub.com) is owned by Guardian Financial Publishing LLC, a limited liability company. Pursuant to an agreement between Guardian Financial Publishing LLC and TD Media Media LLC, Guardian Financial Publishing LLC has been hired for a period beginning on 11/07/2022 and ending on 11/09/2022 to publicly disseminate information about (ATNM:US) via digital communications. We have been paid an additional ten thousand dollars USD via bank wire transfer. To date we have been paid ten thousand dollars USD via bank wire transfer to disseminate information about (ATNM:US) via digital communications. We own zero shares of (ATNM:US). Guardian Financial Publishing 3571 Far West Blvd Austin, TX 78731 United States This email was sent to {EMAIL}. Don't want to receive these emails anymore? [Unsubscribe]( [Privacy Policy]( | [Terms]( | [Risk Disclosure](